ArticleThe oncologist2019
Efficacy of Split Schedule Versus Conventional Schedule Neoadjuvant Cisplatin-Based Chemotherapy for Muscle-Invasive Bladder Cancer.
Article in The oncologist, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Prediction of pathological response following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: the PRE-PREVENCYS trial.BMC cancer · 2021Trial
- Significance of split-dose cisplatin-based neoadjuvant chemotherapy followed by robotic-assisted radical cystectomy for muscle invasive bladder cancer.Translational andrology and urology · 2025Article
- Review
- Eligibility Criteria for Different Platinum-Based Chemotherapy Regimens in Metastatic Urothelial Carcinoma.Cureus · 2024Article
- Management of urothelial cancer in patients with chronic kidney disease receiving platinum-based chemotherapy.Future oncology (London, England) · 2024Review
- Perioperative systemic therapy in muscle invasive bladder cancer: Current standard method, biomarkers and emerging strategies.Investigative and clinical urology · 2023Review
- [Perioperative systemic treatment of urothelial cancer].Urologie (Heidelberg, Germany) · 2023Article
- Refining neoadjuvant therapy clinical trial design for muscle-invasive bladder cancer before cystectomy: a joint US Food and Drug Administration and Bladder Cancer Advocacy Network workshop.Nature reviews. Urology · 2022Review
- Understanding the Barriers to Neoadjuvant Chemotherapy in Patients with Muscle Invasive Bladder Cancer: A Quality Improvement Initiative.Urology practice · 2021Article
- Defining cisplatin eligibility in patients with muscle-invasive bladder cancer.Nature reviews. Urology · 2021Review
- The Quest for an Ideal Neoadjuvant Systemic Therapy in Cisplatin-Ineligible Patients with Muscle-Invasive Localized Urothelial Carcinoma.The oncologist · 2019Article
- Practice patterns and outcomes of conventional versus split-dose cisplatin in neoadjuvant ddMVAC in bladder cancer.Bladder cancer (Amsterdam, Netherlands)Article
Corrections and comments
- Commented on by
Authors and funding
16 authors.
Funding
Abstract
Neoadjuvant cisplatin-based chemotherapy (NAC; 70 mg/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.